WebFeb 23, 2024 · Cytokinetics Announces Start of SEQUOIA-HCM, a Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy. Pivotal Trial to Assess the Potential of Aficamten to Improve Exercise … WebApr 10, 2024 · The candidate is also being evaluated in non-obstructive HCM and the company plans to begin a phase III study later this year. Cytokinetics currently carries a Zacks Rank #3 (Hold).
Cytokinetics Presents Positive Results From Cohort 4 of REDWOOD-HCM …
WebApr 3, 2024 · Cytokinetics, Incorporated announced that the full results from Cohort 3 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), the Phase II clinical trial of aficamten in patients with obstructive hypertrophic cardiomyopathy (HCM), were presented in a Moderated Poster Session by … WebHHMI’s Janelia Research Campus in Ashburn, Virginia, cracks open scientific fields by breaking through technical and intellectual barriers. Our integrated teams of lab scientists … biopsy clip placement
Cytokinetics Announces Cohort 4 of REDWOOD-HCM Is …
WebSep 26, 2024 · HCM Clinical Trials – the Latest News Positive Signs from REDWOOD-HCM Cytokinetics Moves Forward with HCM Drug Trial Recently, Cynthia Waldman of HCMBeat had the opportunity to speak over Zoom with Dr. Martin Maron, who recently served as the principal investigator of Cytokinetics’ REDWOOD trial. WebJul 19, 2024 · Shares in Cytokinetics surged after it reported positive mid-stage results for CK-274, a drug for hypertrophic cardiomyopathy (HCM) that could tread on the toes of Bristol-Myers Squibb's... WebApr 10, 2024 · SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 22 nd Annual Needham Virtual Healthcare Conference on Monday, April 17, 2024 at 10:00 AM Eastern … biopsy containers for formalin